Health Care·Pharmaceuticals·$789.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.83 | N/A | -3.38% |
management commentary, guidance changes, and full analysis available with Pro.
| -3.38% |
Tone: Defensive
Management expressed caution regarding current market conditions. They are committed to navigating challenges while focusing on future growth.
Management highlighted ongoing challenges in the market.
They emphasized a focus on long-term growth despite short-term hurdles.
This earnings report indicates that Eli Lilly faced some challenges, as evidenced by the EPS miss. The lack of revenue data and guidance updates leaves investors with limited insight into future performance. The stock reaction is not available, which may reflect uncertainty in the market.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
LABCORP HLDGS INC
Apr 25, 2016